These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36269550)

  • 1. A Retrospective Analysis of Applications for Registration of Generic Medicines Processed by the Medicines Control Authority of Zimbabwe.
    Samunda BT; Sithole T; Khoza S
    Ther Innov Regul Sci; 2023 Mar; 57(2):287-294. PubMed ID: 36269550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence Common Deficiencies in Generic Products Submitted for Registration to the South African Health Products Regulatory Authority (SAHPRA).
    Moeti L; Litedu M; Joubert J
    Ther Innov Regul Sci; 2022 Sep; 56(5):822-838. PubMed ID: 35896784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the registration process of the medicines control authority of Zimbabwe with Australia, Canada, Singapore, and Switzerland: benchmarking best practices.
    Sithole T; Salek S; Mahlangu G; Walker S
    Expert Rev Clin Pharmacol; 2022 Jan; 15(1):109-119. PubMed ID: 34645359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common Deficiencies Found in the Active Pharmaceutical Ingredient (API) Section of Non-sterile Generic Products Submitted for Registration by SAHPRA.
    Moeti L; Litedu M; Joubert J
    Ther Innov Regul Sci; 2022 Mar; 56(2):276-290. PubMed ID: 34859393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Regulatory Review Process in Zimbabwe: Challenges and Opportunities.
    Sithole T; Mahlangu G; Salek S; Walker S
    Ther Innov Regul Sci; 2021 May; 55(3):474-489. PubMed ID: 33387356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common deficiencies found in generic Finished Pharmaceutical Product (FPP) applications submitted for registration to the South African Health Products Regulatory Authority (SAHPRA).
    Moeti L; Litedu M; Joubert J
    J Pharm Policy Pract; 2022 Jan; 15(1):6. PubMed ID: 35022074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contents of US Food and Drug Administration Refuse-to-File Letters for New Drug Applications and Efficacy Supplements and Their Public Disclosure by Applicants.
    Chahal HS; Mukherjee S; Sigelman DW; Temple R
    JAMA Intern Med; 2021 Apr; 181(4):522-529. PubMed ID: 33587091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common chemistry, manufacturing, and control deficiencies in abbreviated new drug applications assessed by the US Food and drug administration: Hurdle to access cost-effective medicines.
    Kulkarni SB; Gaikwad VL
    J Pharmacol Toxicol Methods; 2023; 123():107295. PubMed ID: 37468082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic Medicines in Croatia--Regulatory Aspects and Statistics.
    Zulfikari S; Sučić AF; Meštrović K; Barbarić MP; Mandarić V; Zorić N; Tomić S
    Coll Antropol; 2015 Jun; 39(2):363-70. PubMed ID: 26753452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory registration timelines of generic medicines in South Africa: Assessment of the performance of SAHPRA between 2011 and 2022.
    Moeti L; Litedu M; Joubert J
    J Pharm Policy Pract; 2023 Mar; 16(1):34. PubMed ID: 36864490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient regulatory approval of two novel HIV prevention interventions in a resource-limited setting: experiences from Zimbabwe.
    Murombedzi C; Chirinda L; Chareka GT; Chirenje ZM; Mgodi NM
    Front Reprod Health; 2023; 5():1279124. PubMed ID: 38034413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical Industry Evaluation of the Effectiveness and Efficiency of the ZaZiBoNa Collaborative Medicines Registration Initiative: The Way Forward.
    Sithole T; Mahlangu G; Walker S; Salek S
    Front Med (Lausanne); 2022; 9():898725. PubMed ID: 35547215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Main Reasons for Registration Application Refusal of Generic and Similar Pharmaceutical Drug Products by the Brazilian Health Regulatory Agency (ANVISA).
    do Carmo AC; Piras SS; Rocha NF; Gratieri T
    Biomed Res Int; 2017; 2017():7894937. PubMed ID: 28280742
    [No Abstract]   [Full Text] [Related]  

  • 15. Review of quality deficiencies found in active pharmaceutical ingredient master files submitted to the WHO Prequalification of Medicines Programme.
    Ortega Diego I; Fake A; Stahl M; Rägo L
    J Pharm Pharm Sci; 2014; 17(2):169-86. PubMed ID: 24934546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Navigating regulatory landscape: A qualitative exploration of medical devices and in vitro diagnostic medical devices oversight in Zimbabwe through key stakeholder perspectives.
    Chiku C; Maruta T; Mbiba F; Manasa J
    PLoS One; 2024; 19(5):e0287415. PubMed ID: 38753856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic medicines: issues and relevance for global health.
    Rana P; Roy V
    Fundam Clin Pharmacol; 2015 Dec; 29(6):529-42. PubMed ID: 26405851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effectiveness and efficiency of the East African community joint assessment procedure by pharmaceutical companies: Opportunities for improvement.
    Ngum N; Mashingia J; Ndomondo-Sigonda M; Walker S; Salek S
    Front Pharmacol; 2022; 13():1031289. PubMed ID: 36408267
    [No Abstract]   [Full Text] [Related]  

  • 19. Statistics, Quality Review Issues, and Beyond for Generic Drug Applications in Taiwan.
    Chang LC; Gau CS
    Ther Innov Regul Sci; 2013 Nov; 47(6):670-677. PubMed ID: 30235552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing operational readiness: Regulatory landscape and compliance in zimbabwe for medical devices and in vitro diagnostic medical devices.
    Chiku C; Maruta T; Mbiba F; Manasa J
    PLoS One; 2024; 19(5):e0287495. PubMed ID: 38753597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.